Immediate vs delayed azathioprine or rituximab for children with anti-MOG attacks
Part of Immune system & allergy clinical trials.
This Phase 3 trial tests whether starting anti-inflammatory treatment right away is better than waiting, using either azathioprine or rituximab, for children with anti-MOG antibody–related acute demyelinating episodes. It may help reduce future attacks and disability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is 6 to under 18 years old
- Child weighs at least 20 kg
- Anti-MOG antibodies are confirmed, and symptoms started more than 24 hours ago from an inflammation-related episode (such as optic neuritis, spinal cord inflammation, brainstem/rhombencephalitis, ADEM, or NMOSD)
- Child has not had any treatment for this episode yet, except steroids
- Child’s disability score (EDSS) is under 5.5 at screening, and blood tests (immune cells, platelets, hemoglobin, kidney and liver function) are above required minimums
- No certain ongoing problems: no active infections like COVID-19, TB, hepatitis B/C, or HIV; no prior serious allergy to azathioprine/rituximab; and no uncontrolled cancer or uncontrolled blood pressure/heart issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies whether azathioprine can help prevent problems after a first attack of MOG antibody–related inflammation of the brain/spinal cord. It’s for adults with a recent first episode and confirmed MOG antibodies.
This trial tests whether a combination of steroid medicine (corticosteroid) and a targeted immune drug (rituximab) can prevent mild eye-muscle weakness from spreading to other muscles. It is for people newly diagnosed with ocular myasthenia who have not yet taken immune-suppressing treatments.
This trial tests whether a drug called rituximab can help children with their first episode of nephrotic syndrome stay in remission longer. It is for children who have already responded to steroid treatment.
This trial studies whether inebilizumab can reduce illness activity in children with neuromyelitis optica spectrum disorder (NMOSD), a condition that can cause attacks affecting the eyes and spinal cord. It focuses on kids who have had recent relapses, meaning symptoms came back or worsened.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
Hear when a new Acute Demyelinating Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.